Comparison of complication rates of Hickman® catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy

Ming Y. Lim, Aref Al-Kali, Aneel Arjun Ashrani, Kebede Begna, Michelle A. Elliott, William Hogan, C. Christopher Hook, Scott H Kaufmann, Louis Letendre, Mark R Litzow, Mrinal M Patnaik, Animesh D Pardanani, Ayalew Tefferi, Alexandra P. Wolanskyj, Diane E. Grill, Rajiv K. Pruthi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Central venous access devices (CVADs) are used for intravenous therapy in patients with hematological malignancies. There are limited data comparing catheter outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. A retrospective review comparing the incidence of early and late CVAD-associated complications and their effect on CVAD removal was performed in patients with AML undergoing induction chemotherapy between 2007 and 2011. Overall, 64 Hickman® catheters and 84 peripherally inserted central catheters (PICCs) were inserted. There was a trend toward increasing use of PICCs. The rate of CVAD occlusion was higher in PICCs compared to Hickman catheters (48.2% vs. 3.2%), for a rate of 20.43 vs. 1.25 per 1000 CVAD-days (p = 0.0001). There was no significant difference in the rates of CVAD-associated thrombosis, premature removal, blood stream infection (BSI) and CVAD-related BSI. Importantly, there was no significant difference in the rate of CVAD removal between Hickman catheters and PICCs for the duration that the CVADs were in place. The choice of type of CVAD inserted into patients with newly diagnosed AML will depend on ease of catheter placement, cost, perception of frequency and severity of complications, and clinician preference.

Original languageEnglish (US)
Pages (from-to)1263-1267
Number of pages5
JournalLeukemia and Lymphoma
Volume54
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Induction Chemotherapy
Acute Myeloid Leukemia
Catheters
Equipment and Supplies
Device Removal
Central Venous Catheters
Hematologic Neoplasms
Infection
Thrombosis
Costs and Cost Analysis
Incidence

Keywords

  • Acute myeloid leukemia
  • Complication rates
  • CVAD

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Comparison of complication rates of Hickman® catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. / Lim, Ming Y.; Al-Kali, Aref; Ashrani, Aneel Arjun; Begna, Kebede; Elliott, Michelle A.; Hogan, William; Hook, C. Christopher; Kaufmann, Scott H; Letendre, Louis; Litzow, Mark R; Patnaik, Mrinal M; Pardanani, Animesh D; Tefferi, Ayalew; Wolanskyj, Alexandra P.; Grill, Diane E.; Pruthi, Rajiv K.

In: Leukemia and Lymphoma, Vol. 54, No. 6, 06.2013, p. 1263-1267.

Research output: Contribution to journalArticle

@article{2350d1934c0c4af49323c3aab113c8f2,
title = "Comparison of complication rates of Hickman{\circledR} catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy",
abstract = "Central venous access devices (CVADs) are used for intravenous therapy in patients with hematological malignancies. There are limited data comparing catheter outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. A retrospective review comparing the incidence of early and late CVAD-associated complications and their effect on CVAD removal was performed in patients with AML undergoing induction chemotherapy between 2007 and 2011. Overall, 64 Hickman{\circledR} catheters and 84 peripherally inserted central catheters (PICCs) were inserted. There was a trend toward increasing use of PICCs. The rate of CVAD occlusion was higher in PICCs compared to Hickman catheters (48.2{\%} vs. 3.2{\%}), for a rate of 20.43 vs. 1.25 per 1000 CVAD-days (p = 0.0001). There was no significant difference in the rates of CVAD-associated thrombosis, premature removal, blood stream infection (BSI) and CVAD-related BSI. Importantly, there was no significant difference in the rate of CVAD removal between Hickman catheters and PICCs for the duration that the CVADs were in place. The choice of type of CVAD inserted into patients with newly diagnosed AML will depend on ease of catheter placement, cost, perception of frequency and severity of complications, and clinician preference.",
keywords = "Acute myeloid leukemia, Complication rates, CVAD",
author = "Lim, {Ming Y.} and Aref Al-Kali and Ashrani, {Aneel Arjun} and Kebede Begna and Elliott, {Michelle A.} and William Hogan and Hook, {C. Christopher} and Kaufmann, {Scott H} and Louis Letendre and Litzow, {Mark R} and Patnaik, {Mrinal M} and Pardanani, {Animesh D} and Ayalew Tefferi and Wolanskyj, {Alexandra P.} and Grill, {Diane E.} and Pruthi, {Rajiv K.}",
year = "2013",
month = "6",
doi = "10.3109/10428194.2012.742520",
language = "English (US)",
volume = "54",
pages = "1263--1267",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Comparison of complication rates of Hickman® catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy

AU - Lim, Ming Y.

AU - Al-Kali, Aref

AU - Ashrani, Aneel Arjun

AU - Begna, Kebede

AU - Elliott, Michelle A.

AU - Hogan, William

AU - Hook, C. Christopher

AU - Kaufmann, Scott H

AU - Letendre, Louis

AU - Litzow, Mark R

AU - Patnaik, Mrinal M

AU - Pardanani, Animesh D

AU - Tefferi, Ayalew

AU - Wolanskyj, Alexandra P.

AU - Grill, Diane E.

AU - Pruthi, Rajiv K.

PY - 2013/6

Y1 - 2013/6

N2 - Central venous access devices (CVADs) are used for intravenous therapy in patients with hematological malignancies. There are limited data comparing catheter outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. A retrospective review comparing the incidence of early and late CVAD-associated complications and their effect on CVAD removal was performed in patients with AML undergoing induction chemotherapy between 2007 and 2011. Overall, 64 Hickman® catheters and 84 peripherally inserted central catheters (PICCs) were inserted. There was a trend toward increasing use of PICCs. The rate of CVAD occlusion was higher in PICCs compared to Hickman catheters (48.2% vs. 3.2%), for a rate of 20.43 vs. 1.25 per 1000 CVAD-days (p = 0.0001). There was no significant difference in the rates of CVAD-associated thrombosis, premature removal, blood stream infection (BSI) and CVAD-related BSI. Importantly, there was no significant difference in the rate of CVAD removal between Hickman catheters and PICCs for the duration that the CVADs were in place. The choice of type of CVAD inserted into patients with newly diagnosed AML will depend on ease of catheter placement, cost, perception of frequency and severity of complications, and clinician preference.

AB - Central venous access devices (CVADs) are used for intravenous therapy in patients with hematological malignancies. There are limited data comparing catheter outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. A retrospective review comparing the incidence of early and late CVAD-associated complications and their effect on CVAD removal was performed in patients with AML undergoing induction chemotherapy between 2007 and 2011. Overall, 64 Hickman® catheters and 84 peripherally inserted central catheters (PICCs) were inserted. There was a trend toward increasing use of PICCs. The rate of CVAD occlusion was higher in PICCs compared to Hickman catheters (48.2% vs. 3.2%), for a rate of 20.43 vs. 1.25 per 1000 CVAD-days (p = 0.0001). There was no significant difference in the rates of CVAD-associated thrombosis, premature removal, blood stream infection (BSI) and CVAD-related BSI. Importantly, there was no significant difference in the rate of CVAD removal between Hickman catheters and PICCs for the duration that the CVADs were in place. The choice of type of CVAD inserted into patients with newly diagnosed AML will depend on ease of catheter placement, cost, perception of frequency and severity of complications, and clinician preference.

KW - Acute myeloid leukemia

KW - Complication rates

KW - CVAD

UR - http://www.scopus.com/inward/record.url?scp=84877752605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877752605&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.742520

DO - 10.3109/10428194.2012.742520

M3 - Article

VL - 54

SP - 1263

EP - 1267

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -